Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Zura Bio Limited (ZURA)

5.54 -0.18 (-3.15%)
At close: 4:00:00 PM EDT
5.63 +0.09 (+1.57%)
After hours: 4:42:56 PM EDT
Trade ZURA on Coinbase
Chart Range Bar
Loading chart for ZURA
  • Previous Close 5.72
  • Open 5.68
  • Bid 5.74 x 100
  • Ask 7.10 x 200
  • Day's Range 5.39 - 5.68
  • 52 Week Range 1.88 - 7.44
  • Volume 1,378,211
  • Avg. Volume 1,296,200
  • Market Cap (intraday) 530.893M
  • Beta (5Y Monthly) -0.03
  • PE Ratio (TTM) --
  • EPS (TTM) -1.12
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 18.00

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

zurabio.com

40

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/31/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ZURA
5.73%
S&P 500 (^GSPC)
12.28%

1-Year Return

ZURA
171.57%
S&P 500 (^GSPC)
18.98%

3-Year Return

ZURA
19.48%
S&P 500 (^GSPC)
70.51%

5-Year Return

ZURA
30.23%
S&P 500 (^GSPC)
69.95%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -24.22M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

-20M
-15M
-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

11.00
18.00 Average
5.54 Current
26.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/12/2026
Analyst Wedbush
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 15 -> 22

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    560.12M

  • Enterprise Value

    354.99M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.84

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -31.23%

  • Return on Equity (ttm)

    -51.01%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -116.44M

  • Diluted EPS (ttm)

    -1.12

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    205.13M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -48.82M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

5.54 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: